Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate

Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: علیرضا خبازی اسکویی , آیدا مالک مهدوی

کلمات کلیدی: alendronate, osteocalcin, osteoporosis

نشریه: 0 , 2 , 3 , 2018

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله آیدا مالک مهدوی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های بافت همبند
کد مقاله 62555
عنوان فارسی مقاله Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate
عنوان لاتین مقاله Serum osteocalcin levels in postmenopausal osteoporotic women receiving alendronate
ناشر 3
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق) Rheumatology Research Journal
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح چهار – SID/Iranmedex/Magiran
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Osteoporosis is characterized by low bone mass, changes in the microscopic structure of bone, and increased bone fragility. Monitoring response to treatment is critical for the appropriate management of osteoporosis. Serum osteocalcin has become known as a bone formation biomarker for the evaluation of treatment response in postmenopausal osteoporosis. The present study assessed the effect of alendronate on serum osteocalcin levels in patients with postmenopausal osteoporosis. Thirty-four women with postmenopausal osteoporosis diagnosed by DEXA received alendronate 10 mg/day for 3 months. Serum osteocalcin, calcium, phosphorus, and alkaline phosphatase (ALP) were measured at baseline and after 45 and 90 days. Mean age and duration of menopause were 57.91±7.68 and 9.37±8.43 years, respectively. Mean serum osteocalcin at baseline was 15.27±3.7 ng/ml, which decreased significantly after 45 and 90 days of treatment with alendronate (p=0.009 and p<0.001, respectively). The levels of serum osteocalcin at days 45 and 90 in patients aged < 60 and ≥ 60 years were not significantly different. The levels of serum osteocalcin at days 45 and 90 in patients with a menopause duration of < 5 and ≥ 5 years were not significantly different. No significant difference was observed in serum osteocalcin levels at days 45 and 90 in patients with osteoporosis only in the femoral neck (n=7), only in the lumbar spine (n=20), and in both femoral neck and lumbar spine (n=7). Measurement of serum osteocalcin is a less expensive, more available tool for monitoring the results of treatment in osteoporotic patients. It provides a practical suggestion about the effectiveness of treatment earlier than densitometry. As expected, osteocalcin levels decreased after treatment of osteoporosis.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
علیرضا خبازی اسکوییدوم
آیدا مالک مهدویسوم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
RR_Volume 3_Issue 2_Pages 83-89.pdf1396/12/27557499دانلود